Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000596 · ClinicalTrials.gov registry record · Phase 2
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02000596 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 2 participants.
The verdict
NCT02000596, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.
Interventions
- DRUG Trastuzumab plus Pertuzumab
- DRUG Hormonal Therapy with Anastrozole and Fulvestrant
- DRUG Chemotherapy with Eribulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000596
The ClinicalTrials.gov registry entry for NCT02000596 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab plus Pertuzumab is the first listed.
NCT02000596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02000596 about?
NCT02000596 is a clinical study titled "1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.". This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.
What is the current status of trial NCT02000596?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2014-01. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02000596?
The interventions under investigation include: Trastuzumab plus Pertuzumab (DRUG), Hormonal Therapy with Anastrozole and Fulvestrant (DRUG), Chemotherapy with Eribulin (DRUG).
Who is sponsoring clinical trial NCT02000596?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.